But even as Ozempic enters India, there is a growing sense globally that Novo may have already lost the obesity drug war to ...

In an interview, Novo Nordisk India’s managing director Vikrant Shrotriya discusses the launch of Ozempic, the company’s ...

Novo Nordisk says it is taking a flexible portfolio approach and plans to price the injectable semaglutide close to Wegovy’s ...

Semaglutide and tirzepatide, the latter marketed by US-based Eli Lilly in India as Mounjaro, belong to the GLP-1 class of ...

There’s trouble brewing beneath the GLP-1 buzz. As Americans embrace blockbuster weight-loss drugs like Ozempic and Wegovy in ...

Northwell Health reports that "Ozempic face" describes the facial changes from rapid weight loss using Ozempic, highlighting ...

A Division Bench of Delhi High Court on Friday declined to stay a Single Judge’s order that had allowed Dr Reddy’s ...

The maker of the weight loss and diabetes drugs Wegovy and Ozempic has cut the prices for most versions of the blockbuster medications.

Usage of GLP-1 medications has increased over the past 18 months, with highest adoption among women and adults aged 50-64, ...

New weight-loss drugs promise transformative benefits, but soaring demand and massive cost projections leave Ireland facing ...

Ozempic is finally here — but it doesn’t come cheap. With costs touching ₹11,000 a month and generics still a year away, here ...

Novo Nordisk launches Ozempic in India, targeting the fast-growing diabetes and obesity market ahead of generic competition.